{"id":457325,"date":"2021-03-15T07:03:40","date_gmt":"2021-03-15T11:03:40","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=457325"},"modified":"2021-03-15T07:03:40","modified_gmt":"2021-03-15T11:03:40","slug":"scopus-biopharma-finalizes-arrangements-for-submission-of-ind-package","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/scopus-biopharma-finalizes-arrangements-for-submission-of-ind-package\/","title":{"rendered":"Scopus BioPharma Finalizes Arrangements for Submission of IND Package"},"content":{"rendered":"
\n

Submission to FDA Expected in Q2 2021<\/h2>\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n NEW YORK<\/span>, March 15, 2021<\/span> \/PRNewswire\/ —\u00a0Scopus BioPharma Inc. (Nasdaq: “SCPS”)<\/b> today announced the finalization of arrangements for the completion of the investigational new drug (“IND”) package for the company’s lead drug candidate and its submission to the United States Food and Drug Administration (“FDA”).\u00a0The IND submission is expected in Q2 2021.<\/p>\n

\n

\n
\n \"(PRNewsfoto\/Scopus
\n <\/a>\n <\/p>\n<\/p><\/div>\n

Scopus is a biopharmaceutical company developing transformational therapeutics based on groundbreaking scientific and medical discoveries.\u00a0The company’s lead drug candidate is a novel, targeted immuno-oncology gene therapy for the treatment of multiple cancers.<\/p>\n

\n Joshua R. Lamstein<\/span>, Chairman of Scopus BioPharma, stated, “We are extremely excited about the forthcoming submission of the IND for the Phase 1 clinical trial for our lead drug candidate.\u00a0We believe investors will recognize this milestone as an important near-term driver of shareholder value.”<\/p>\n

The company’s lead drug candidate is highly distinctive, encompassing both gene therapy and immunotherapy by synthetically linking siRNA to an oligonucleotide TLR9 agonist, creating the potential for targeted gene silencing with simultaneous TLR stimulation and immune activation in the tumor microenvironment.<\/p>\n

\n About Scopus BioPharma<\/b>\n <\/p>\n

Scopus BioPharma Inc. is a biopharmaceutical company developing transformational therapeutics capitalizing on groundbreaking scientific and medical discoveries from leading research and academic institutions.\u00a0The company’s lead drug candidate is a novel, targeted immuno-oncology gene therapy for the treatment of multiple cancers.\u00a0This drug candidate is highly distinctive, encompassing both gene therapy and immunotherapy by synthetically linking siRNA to an oligonucleotide TLR9 agonist, creating the potential for targeted gene silencing with simultaneous TLR stimulation and immune activation in the tumor microenvironment.\u00a0The company is also developing additional new chemical entities to treat other serious diseases with significant unmet medical needs, including systemic sclerosis.\u00a0Receive updates by following Scopus BioPharma on Twitter here<\/a>.<\/p>\n

\n Forward-Looking Statements<\/b>\n <\/p>\n

This press release may include forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks (including those set forth in the company’s offering circular filed with the U.S. Securities and Exchange Commission) and uncertainties which could cause actual results to differ from the forward-looking statements. The company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. Investors should realize that if our underlying assumptions for the projections contained herein prove inaccurate or that known or unknown risks or uncertainties materialize, actual results could vary materially from our expectations and projections.<\/p>\n

\n Contact<\/b>\n <\/p>\n

\n Rodd Leeds<\/span>\/David Waldman<\/span>
Crescendo Communications, LLC
Tel: (212) 671-1020
Email: SCPS@crescendo-ir.com<\/a><\/p>\n

<\/div>\n

\n \"Cision\" View original content to download multimedia:http:\/\/www.prnewswire.com\/news-releases\/scopus-biopharma-finalizes-arrangements-for-submission-of-ind-package-301247064.html<\/a><\/p>\n

SOURCE Scopus BioPharma Inc.<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Submission to FDA Expected in Q2 2021 PR Newswire NEW YORK, March 15, 2021 \/PRNewswire\/ —\u00a0Scopus BioPharma Inc. (Nasdaq: “SCPS”) today announced the finalization of arrangements for the completion of the investigational new drug (“IND”) package for the company’s lead drug candidate and its submission to the United States Food and Drug Administration (“FDA”).\u00a0The IND submission is expected in Q2 2021. Scopus is a biopharmaceutical company developing transformational therapeutics based on groundbreaking scientific and medical discoveries.\u00a0The company’s lead drug candidate is a novel, targeted immuno-oncology gene therapy for the treatment of multiple cancers. Joshua R. Lamstein, Chairman of Scopus BioPharma, stated, “We are extremely excited about the forthcoming submission of the IND for the Phase 1 clinical trial for our … <\/p>\n

Continue reading “Scopus BioPharma Finalizes Arrangements for Submission of IND Package”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-457325","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nScopus BioPharma Finalizes Arrangements for Submission of IND Package - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/scopus-biopharma-finalizes-arrangements-for-submission-of-ind-package\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Scopus BioPharma Finalizes Arrangements for Submission of IND Package - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Submission to FDA Expected in Q2 2021 PR Newswire NEW YORK, March 15, 2021 \/PRNewswire\/ —\u00a0Scopus BioPharma Inc. (Nasdaq: “SCPS”) today announced the finalization of arrangements for the completion of the investigational new drug (“IND”) package for the company’s lead drug candidate and its submission to the United States Food and Drug Administration (“FDA”).\u00a0The IND submission is expected in Q2 2021. Scopus is a biopharmaceutical company developing transformational therapeutics based on groundbreaking scientific and medical discoveries.\u00a0The company’s lead drug candidate is a novel, targeted immuno-oncology gene therapy for the treatment of multiple cancers. Joshua R. Lamstein, Chairman of Scopus BioPharma, stated, “We are extremely excited about the forthcoming submission of the IND for the Phase 1 clinical trial for our … Continue reading "Scopus BioPharma Finalizes Arrangements for Submission of IND Package"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/scopus-biopharma-finalizes-arrangements-for-submission-of-ind-package\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-15T11:03:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/1179734\/Scopus_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scopus-biopharma-finalizes-arrangements-for-submission-of-ind-package\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scopus-biopharma-finalizes-arrangements-for-submission-of-ind-package\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Scopus BioPharma Finalizes Arrangements for Submission of IND Package\",\"datePublished\":\"2021-03-15T11:03:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scopus-biopharma-finalizes-arrangements-for-submission-of-ind-package\\\/\"},\"wordCount\":471,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scopus-biopharma-finalizes-arrangements-for-submission-of-ind-package\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1179734\\\/Scopus_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scopus-biopharma-finalizes-arrangements-for-submission-of-ind-package\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scopus-biopharma-finalizes-arrangements-for-submission-of-ind-package\\\/\",\"name\":\"Scopus BioPharma Finalizes Arrangements for Submission of IND Package - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scopus-biopharma-finalizes-arrangements-for-submission-of-ind-package\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scopus-biopharma-finalizes-arrangements-for-submission-of-ind-package\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1179734\\\/Scopus_Logo.jpg\",\"datePublished\":\"2021-03-15T11:03:40+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scopus-biopharma-finalizes-arrangements-for-submission-of-ind-package\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scopus-biopharma-finalizes-arrangements-for-submission-of-ind-package\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scopus-biopharma-finalizes-arrangements-for-submission-of-ind-package\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1179734\\\/Scopus_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1179734\\\/Scopus_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scopus-biopharma-finalizes-arrangements-for-submission-of-ind-package\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Scopus BioPharma Finalizes Arrangements for Submission of IND Package\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Scopus BioPharma Finalizes Arrangements for Submission of IND Package - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/scopus-biopharma-finalizes-arrangements-for-submission-of-ind-package\/","og_locale":"en_US","og_type":"article","og_title":"Scopus BioPharma Finalizes Arrangements for Submission of IND Package - Market Newsdesk","og_description":"Submission to FDA Expected in Q2 2021 PR Newswire NEW YORK, March 15, 2021 \/PRNewswire\/ —\u00a0Scopus BioPharma Inc. (Nasdaq: “SCPS”) today announced the finalization of arrangements for the completion of the investigational new drug (“IND”) package for the company’s lead drug candidate and its submission to the United States Food and Drug Administration (“FDA”).\u00a0The IND submission is expected in Q2 2021. Scopus is a biopharmaceutical company developing transformational therapeutics based on groundbreaking scientific and medical discoveries.\u00a0The company’s lead drug candidate is a novel, targeted immuno-oncology gene therapy for the treatment of multiple cancers. Joshua R. Lamstein, Chairman of Scopus BioPharma, stated, “We are extremely excited about the forthcoming submission of the IND for the Phase 1 clinical trial for our … Continue reading \"Scopus BioPharma Finalizes Arrangements for Submission of IND Package\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/scopus-biopharma-finalizes-arrangements-for-submission-of-ind-package\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-15T11:03:40+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/1179734\/Scopus_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scopus-biopharma-finalizes-arrangements-for-submission-of-ind-package\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scopus-biopharma-finalizes-arrangements-for-submission-of-ind-package\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Scopus BioPharma Finalizes Arrangements for Submission of IND Package","datePublished":"2021-03-15T11:03:40+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scopus-biopharma-finalizes-arrangements-for-submission-of-ind-package\/"},"wordCount":471,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scopus-biopharma-finalizes-arrangements-for-submission-of-ind-package\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1179734\/Scopus_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scopus-biopharma-finalizes-arrangements-for-submission-of-ind-package\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/scopus-biopharma-finalizes-arrangements-for-submission-of-ind-package\/","name":"Scopus BioPharma Finalizes Arrangements for Submission of IND Package - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scopus-biopharma-finalizes-arrangements-for-submission-of-ind-package\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scopus-biopharma-finalizes-arrangements-for-submission-of-ind-package\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1179734\/Scopus_Logo.jpg","datePublished":"2021-03-15T11:03:40+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scopus-biopharma-finalizes-arrangements-for-submission-of-ind-package\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/scopus-biopharma-finalizes-arrangements-for-submission-of-ind-package\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scopus-biopharma-finalizes-arrangements-for-submission-of-ind-package\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/1179734\/Scopus_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/1179734\/Scopus_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scopus-biopharma-finalizes-arrangements-for-submission-of-ind-package\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Scopus BioPharma Finalizes Arrangements for Submission of IND Package"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/457325","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=457325"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/457325\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=457325"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=457325"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=457325"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}